ArticleBiopolymers2026
Enzymatically Synthesized Poly(Gallic Acid) Modulates Methionine Synthase Activity and Neuroblastoma Morphology in Contrast to Phthalate-Type Endocrine Disruptors.
Article in Biopolymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The effect of the enzyme-mediated poly(gallic acid) (PGAL) as a potential redox regulator or redox activity compound (RAC) on the morphology of human neuroblastoma SH-SY5Y cells and its methionine synthase (MS) activities is contrasted to those for disrupting compounds (EDC). For that, we study the effects of di(2-ethylhexyl)phthalate (DEHP) and monobutylphthalate (MBP) as common EDCs. The results show the expected significant decrease in cell density and predominance of phenotype N associated with shorter neurites after exposure to EDCs; however, homogeneous cell density and an S phenotype consistent with the control are observed after exposure to the polymeric RAC, and compared to other reported RAC metabolites, sulforaphane (SFN) and its precursor gallic acid (GA). Regarding the enzymatic activity of MS, a 64% increase is observed in the presence of EDCs. Surprisingly, control GA also shows a 35% increase in MS enzymatic activity, but this stable multiradical polyanion derivative has an average decrease of 51%. To the best of our knowledge, this is the first time that MS enzymatic activities-to-risk of endocrine disruption relationships, compared to that of a polymeric RAC, have been established using neuroblastoma cell cultures, laying groundwork for future research in neurobiology and environmental health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.